vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and MERCURY SYSTEMS INC (MRCY). Click either name above to swap in a different company.

MERCURY SYSTEMS INC is the larger business by last-quarter revenue ($232.9M vs $168.4M, roughly 1.4× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.4%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 5.7%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Mercury Systems, Inc. is a technology company serving the aerospace and defense industry. It designs, develops and manufactures open architecture computer hardware and software products, including secure embedded processing modules and subsystems, avionics mission computers and displays, rugged secure computer servers, and trusted microelectronics components, modules and subsystems.

ESPR vs MRCY — Head-to-Head

Bigger by revenue
MRCY
MRCY
1.4× larger
MRCY
$232.9M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+139.4% gap
ESPR
143.7%
4.4%
MRCY
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
5.7%
MRCY

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ESPR
ESPR
MRCY
MRCY
Revenue
$168.4M
$232.9M
Net Profit
$-15.1M
Gross Margin
26.0%
Operating Margin
50.6%
-4.6%
Net Margin
-6.5%
Revenue YoY
143.7%
4.4%
Net Profit YoY
14.1%
EPS (diluted)
$0.32
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
MRCY
MRCY
Q4 25
$168.4M
$232.9M
Q3 25
$87.3M
$225.2M
Q2 25
$82.4M
$273.1M
Q1 25
$65.0M
$211.4M
Q4 24
$69.1M
$223.1M
Q3 24
$51.6M
$204.4M
Q2 24
$73.8M
$248.6M
Q1 24
$137.7M
$208.3M
Net Profit
ESPR
ESPR
MRCY
MRCY
Q4 25
$-15.1M
Q3 25
$-31.3M
$-12.5M
Q2 25
$-12.7M
$16.4M
Q1 25
$-40.5M
$-19.2M
Q4 24
$-17.6M
Q3 24
$-29.5M
$-17.5M
Q2 24
$-61.9M
$-10.8M
Q1 24
$61.0M
$-44.6M
Gross Margin
ESPR
ESPR
MRCY
MRCY
Q4 25
26.0%
Q3 25
27.9%
Q2 25
31.0%
Q1 25
27.0%
Q4 24
27.3%
Q3 24
25.3%
Q2 24
29.5%
Q1 24
19.5%
Operating Margin
ESPR
ESPR
MRCY
MRCY
Q4 25
50.6%
-4.6%
Q3 25
-11.4%
-3.8%
Q2 25
8.6%
8.6%
Q1 25
-34.0%
-8.2%
Q4 24
-6.4%
-5.6%
Q3 24
-31.0%
-6.6%
Q2 24
3.5%
-3.2%
Q1 24
52.5%
-21.9%
Net Margin
ESPR
ESPR
MRCY
MRCY
Q4 25
-6.5%
Q3 25
-35.9%
-5.6%
Q2 25
-15.4%
6.0%
Q1 25
-62.2%
-9.1%
Q4 24
-7.9%
Q3 24
-57.2%
-8.6%
Q2 24
-83.9%
-4.3%
Q1 24
44.3%
-21.4%
EPS (diluted)
ESPR
ESPR
MRCY
MRCY
Q4 25
$0.32
$-0.26
Q3 25
$-0.16
$-0.21
Q2 25
$-0.06
$0.28
Q1 25
$-0.21
$-0.33
Q4 24
$-0.14
$-0.30
Q3 24
$-0.15
$-0.30
Q2 24
$-0.33
$-0.18
Q1 24
$0.34
$-0.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
MRCY
MRCY
Cash + ST InvestmentsLiquidity on hand
$167.9M
$335.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$1.5B
Total Assets
$465.9M
$2.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
MRCY
MRCY
Q4 25
$167.9M
$335.0M
Q3 25
$92.4M
$304.7M
Q2 25
$86.1M
$309.1M
Q1 25
$114.6M
$269.8M
Q4 24
$144.8M
$242.6M
Q3 24
$144.7M
$158.1M
Q2 24
$189.3M
$180.5M
Q1 24
$226.6M
$142.6M
Stockholders' Equity
ESPR
ESPR
MRCY
MRCY
Q4 25
$-302.0M
$1.5B
Q3 25
$-451.4M
$1.5B
Q2 25
$-433.5M
$1.5B
Q1 25
$-426.2M
$1.5B
Q4 24
$-388.7M
$1.5B
Q3 24
$-370.2M
$1.5B
Q2 24
$-344.2M
$1.5B
Q1 24
$-294.3M
$1.5B
Total Assets
ESPR
ESPR
MRCY
MRCY
Q4 25
$465.9M
$2.5B
Q3 25
$364.0M
$2.5B
Q2 25
$347.1M
$2.4B
Q1 25
$324.0M
$2.4B
Q4 24
$343.8M
$2.4B
Q3 24
$314.1M
$2.4B
Q2 24
$352.3M
$2.4B
Q1 24
$373.1M
$2.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
MRCY
MRCY
Operating Cash FlowLast quarter
$45.2M
$51.6M
Free Cash FlowOCF − Capex
$45.7M
FCF MarginFCF / Revenue
19.6%
Capex IntensityCapex / Revenue
0.0%
2.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$99.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
MRCY
MRCY
Q4 25
$45.2M
$51.6M
Q3 25
$-4.3M
$2.2M
Q2 25
$-31.4M
$38.1M
Q1 25
$-22.6M
$30.0M
Q4 24
$-35.0M
$85.5M
Q3 24
$-35.3M
$-14.7M
Q2 24
$-7.2M
$71.8M
Q1 24
$53.8M
$-17.8M
Free Cash Flow
ESPR
ESPR
MRCY
MRCY
Q4 25
$45.7M
Q3 25
$-4.4M
Q2 25
$34.0M
Q1 25
$24.1M
Q4 24
$81.9M
Q3 24
$-35.5M
$-20.9M
Q2 24
$-7.3M
$61.4M
Q1 24
$53.8M
$-25.7M
FCF Margin
ESPR
ESPR
MRCY
MRCY
Q4 25
19.6%
Q3 25
-1.9%
Q2 25
12.4%
Q1 25
11.4%
Q4 24
36.7%
Q3 24
-68.7%
-10.2%
Q2 24
-9.9%
24.7%
Q1 24
39.0%
-12.4%
Capex Intensity
ESPR
ESPR
MRCY
MRCY
Q4 25
0.0%
2.5%
Q3 25
0.0%
2.9%
Q2 25
0.0%
1.5%
Q1 25
0.0%
2.8%
Q4 24
0.0%
1.6%
Q3 24
0.3%
3.1%
Q2 24
0.1%
4.2%
Q1 24
0.1%
3.8%
Cash Conversion
ESPR
ESPR
MRCY
MRCY
Q4 25
Q3 25
Q2 25
2.33×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

MRCY
MRCY

Airborne$84.2M36%
Components$48.7M21%
Other End Applications$36.8M16%
Electronic Warfare$27.5M12%
Other Sensor And Effector Applications$23.9M10%
Space$11.9M5%

Related Comparisons